Compare VTS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | ANNX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 756.5M | 730.4M |
| IPO Year | 2022 | 2020 |
| Metric | VTS | ANNX |
|---|---|---|
| Price | $19.95 | $5.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $26.50 | $16.50 |
| AVG Volume (30 Days) | 441.7K | ★ 2.3M |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.52% | N/A |
| EPS Growth | N/A | ★ 42.94 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $273,989,000.00 | N/A |
| Revenue This Year | $29.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.41 | ★ N/A |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $17.44 | $1.29 |
| 52 Week High | $27.15 | $7.18 |
| Indicator | VTS | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 52.37 |
| Support Level | $19.21 | $4.69 |
| Resistance Level | $20.24 | $5.61 |
| Average True Range (ATR) | 0.80 | 0.29 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 44.42 | 81.58 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.